# US 2021/0171483 A1 · Benzothiadiazepine compounds and their use as bile acid modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171483 A1
- Document ID: US20210171483A1
- Status: Published application
- Kind: A1
- Application number: 17/145,038
- Filed: 2021-01-08
- Published: 2021-06-10
- Earliest claimed: 2019-12-04
- Assignees: Albireo AB
- Applicants: Albireo AB
- Inventors: Per-Göran Gillberg; Ingemar Starke; Santosh S. Kulkarni
- Web page: https://patentgrep.com/patent/US20210171483A1

## CPC

- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- C07D 285/36: Seven-membered rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

## Claims

### Claim 1

A compound of formula (I)
wherein
R1 and R2 are each independently C1-4 alkyl;
R3 is independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, cyano, nitro, amino, N—(C1-4 alkyl)amino, N,N-di(C1-4 alkyl)amino, and N-(aryl-C1-4 alkyl)amino;
n is an integer 1, 2 or 3; and
R4 is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, C3-6 cycloalkyloxy, C1-4 alkylthio, C3-6 cycloalkylthio, amino, N—(C1-4 alkyl)amino and N,N-di(C1-4 alkyl)amino;
or a pharmaceutically acceptable salt thereof,
with the proviso that the compound is not a compound from the group consisting of
2-((3,3-dibutyl-7-methyl-5-phenyl-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acetic acid;
2-((3,3-dibutyl-7-(methylthio)-5-phenyl-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acetic acid; and
2-((7-bromo-3,3-dibutyl-5-phenyl-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acetic acid.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is n-butyl.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R2 is n-butyl.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R2 is ethyl.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R3 is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, C1-4 haloalkyl, C1-4 alkoxy and C1-4 haloalkoxy.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein R3 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, cyano, trifluoromethyl, methoxy and trifluoromethoxy.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein R4 is selected from the group consisting of halogen, hydroxy, cyano, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, amino, N—(C1-4 alkyl)amino and N,N-di(C1-4 alkyl)amino.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein R4 is selected from the group consisting of fluoro, chloro, bromo, hydroxy, cyano, methyl, methoxy, ethoxy, methylthio, ethylthio, amino, methylamino and dimethylamino.

### Claim 9 (depends on 1)

A compound according to claim 1, selected from the group consisting of
2-((3-butyl-3-ethyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo-1,2,5-thiadiazepin-8-yl)oxy)acetic acid;
(S)-2-((3-butyl-3-ethyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acetic acid; and
(R)-2-((3-butyl-3-ethyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acetic acid;
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim 11

(canceled)

### Claim 12 (depends on 17)

The method according to claim 17, wherein the cardiovascular disease or disorder of fatty acid metabolism or glucose utilization disorder is selected from the group consisting of: hypercholesterolemia; a disorder of fatty acid metabolism; type 1 and type 2 diabetes mellitus; a complication of diabetes.

### Claim 13 (depends on 18)

The method according to claim 18, wherein the gastrointestinal disease or disorder is selected from the group consisting of: constipation; Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); ileal inflammation; and reflux disease and complications thereof.

### Claim 14 (depends on 19)

The method according to claim 19, wherein the liver disease or disorder is selected from the group consisting of an inherited metabolic disorder of the liver; inborn errors of bile acid synthesis; congenital bile duct anomalies; biliary atresia; post-Kasai biliary atresia; post-liver transplantation biliary atresia; neonatal hepatitis; neonatal cholestasis; hereditary forms of cholestasis; cerebrotendinous xanthomatosis; a secondary defect of BA synthesis; Zellweger's syndrome; cystic fibrosis-associated liver disease; alpha1-antitrypsin deficiency; Alagilles syndrome (ALGS); Byler syndrome; a primary defect of bile acid (BA) synthesis; progressive familial intrahepatic cholestasis (PFIC); benign recurrent intrahepatic cholestasis (BRIC); autoimmune hepatitis; primary biliary cirrhosis (PBC); liver fibrosis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); portal hypertension; cholestasis; Down syndrome cholestasis; drug-induced cholestasis; intrahepatic cholestasis of pregnancy (jaundice during pregnancy); intrahepatic cholestasis; extrahepatic cholestasis; parenteral nutrition associated cholestasis (PNAC); low phospholipid-associated cholestasis; lymphedema cholestasis syndrome 1 (LSC1); primary sclerosing cholangitis (PSC); immunoglobulin G4 associated cholangitis; primary biliary cholangitis; cholelithiasis (gall stones); biliary lithiasis; choledocholithiasis; gallstone pancreatitis; Caroli disease; malignancy of bile ducts; malignancy causing obstruction of the biliary tree; biliary strictures; AIDS cholangiopathy; ischemic cholangiopathy; pruritus due to cholestasis or jaundice; pancreatitis; chronic autoimmune liver disease leading to progressive cholestasis; hepatic steatosis; alcoholic hepatitis; acute fatty liver; fatty liver of pregnancy; drug-induced hepatitis; iron overload disorders; congenital bile acid synthesis defect type 1 (BAS type 1); drug-induced liver injury (DILI); hepatic fibrosis; congenital hepatic fibrosis; hepatic cirrhosis; Langerhans cell histiocytosis (LCH); neonatal ichthyosis sclerosing cholangitis (NISCH); erythropoietic protoporphyria (EPP); idiopathic adulthood ductopenia (IAD); idiopathic neonatal hepatitis (INH); non syndromic paucity of interlobular bile ducts (NS PILBD); North American Indian childhood cirrhosis (NAIC); hepatic sarcoidosis; amyloidosis; necrotizing enterocolitis; serum bile acid-caused toxicities; polycystic liver disease; viral hepatitis; hepatocellular carcinoma (hepatoma); cholangiocarcinoma; bile acid-related gastrointestinal cancers; and cholestasis caused by tumours and neoplasms of the liver, of the biliary tract and of the pancreas.

### Claim 15 (depends on 16)

The method according to claim 16, wherein the hyperabsorption syndrome is selected from the group consisting of: abetalipoproteinemia, familial hypobetalipoproteinemia (FHBL); chylomicron retention disease (CRD); and sitosterolemia.

### Claim 16

A method for treating a disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I)
wherein
R1 and R2 are each independently C1-4 alkyl;
R3 is independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, cyano, nitro, amino, N—(C1-4 alkyl)amino, N,N-di(C1-4 alkyl)amino, and N-(aryl-C1-4 alkyl)amino;
n is an integer 1, 2 or 3; and
R4 is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, C3-6 cycloalkyloxy, C1-4 alkylthio, C3-6 cycloalkylthio, amino, N—(C1-4 alkyl)amino and N,N-di(C1-4 alkyl)amino;
or a pharmaceutically acceptable salt thereof,
wherein the disease or disorder is selected from the group consisting of a cardiovascular disease; a disorder of fatty acid metabolism; a glucose utilization disorder; a gastrointestinal disease or disorder; a liver disease or disorder; a hyperabsorption syndrome; hypervitaminosis and osteopetrosis; hypertension; glomerular hyperfiltration; or pruritus of renal failure.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the disease or disorder is selected from the group consisting of a cardiovascular disease, a disorder of fatty acid metabolism, and a glucose utilization disorder.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the disease or disorder is a gastrointestinal disease or disorder.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the disease or disorder is a liver disease or disorder.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the liver disease or disorder is a cholestatic liver disease.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the liver disease or disorder is selected from the group consisting of: progressive familial intrahepatic cholestasis (PFIC), Alagilles syndrome, biliary atresia, and non-alcoholic steatohepatitis (NASH).
